Erik H J G Aarntzen Selected Research

Erik H J G Aarntzen Research Topics

Disease

33	Neoplasms (Cancer) 12/2022 - 12/2007
20	Melanoma (Melanoma, Malignant) 03/2020 - 01/2009
3	Infections 01/2022 - 01/2017
3	Hypersensitivity (Allergy) 11/2019 - 09/2011
2	Neoplasm Metastasis (Metastasis) 12/2022 - 05/2012
2	Communicable Diseases (Infectious Diseases) 01/2022 - 11/2011
2	Bacteremia 07/2019 - 01/2017
1	Extranodal Extension 12/2022
1	Adenocarcinoma 10/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2022
1	Disease Progression 10/2022
1	Squamous Cell Carcinoma of Head and Neck 10/2022
1	Staphylococcal Infections 10/2021
1	Musculoskeletal Diseases (Musculoskeletal Disease) 09/2021
1	Hyperaldosteronism (Conn Syndrome) 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Periodontitis 01/2021
1	Arteritis 01/2021
1	Essential Hypertension 01/2021
1	Heart Failure 03/2020
1	Inflammation (Inflammations) 01/2020
1	Atherosclerosis 01/2020
1	Prostatic Neoplasms (Prostate Cancer) 11/2019
1	Foreign Bodies (Foreign Body) 07/2019
1	Fever (Fevers) 07/2019
1	Endocarditis 07/2019
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Breast Neoplasms (Breast Cancer) 10/2018
1	Lymphatic Metastasis 01/2016
1	Uveal melanoma 11/2014
1	Urinary Bladder Neoplasms (Bladder Cancer) 11/2012
1	Vitiligo 01/2009

Drug/Important Bio-Agent (IBA)

14	AntigensIBA 10/2022 - 12/2007
12	Monophenol Monooxygenase (Tyrosinase)IBA 03/2020 - 01/2009
9	Peptides (Polypeptides)IBA 07/2016 - 01/2009
7	VaccinesIBA 03/2020 - 01/2009
6	Messenger RNA (mRNA)IBA 03/2020 - 04/2009
5	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 10/2022 - 01/2017
5	CytokinesIBA 07/2016 - 12/2007
5	Neoplasm Antigens (Tumor Antigens)IBA 03/2016 - 04/2009
4	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 03/2016 - 09/2011
2	B7-H1 AntigenIBA 10/2022 - 01/2019
2	AntibodiesIBA 01/2022 - 01/2019
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2020
2	MART-1 AntigenIBA 08/2014 - 05/2012
2	HLA-A Antigens (HLA-A)IBA 03/2013 - 01/2013
1	durvalumabIBA 10/2022
1	ProgranulinsIBA 10/2022
1	LipopolysaccharidesIBA 01/2022
1	Pentetic Acid (DTPA)FDA LinkGeneric 01/2022
1	Radioisotopes (Radionuclides)IBA 09/2021
1	Growth Differentiation Factor 15IBA 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 03/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	AldosteroneIBA 01/2020
1	Protamines (Protamine Sulfate)FDA Link 11/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 07/2019
1	pembrolizumabIBA 01/2019
1	Everolimus FDA Link 10/2018
1	exemestane (Aromasin)FDA Link 10/2018
1	Dinoprostone (PGE2)FDA Link 03/2016
1	ChemokinesIBA 01/2016
1	Melanoma-Specific AntigensIBA 11/2014
1	Interleukin-4 (Interleukin 4)IBA 08/2014
1	HLA-DR4 Antigen (HLA DR4 Antigen)IBA 01/2013
1	Carrier Proteins (Binding Protein)IBA 11/2012
1	Vaccine AdjuvantsIBA 11/2012
1	HaptensIBA 11/2012
1	Immunoglobulin G (IgG)IBA 11/2012
1	Immunoglobulin M (IgM)IBA 11/2012
1	SurvivinIBA 05/2012
1	Biomarkers (Surrogate Marker)IBA 11/2011
1	InterleukinsIBA 09/2011
1	RNA (Ribonucleic Acid)IBA 07/2009
1	Proteins (Proteins, Gene)FDA Link 07/2009
1	Indium-111IBA 04/2009
1	ferric oxide (iron oxide)IBA 04/2009
1	Differentiation AntigensIBA 01/2009
1	Interleukin-2 (IL2)IBA 01/2009

Therapy/Procedure

13	Immunotherapy 11/2019 - 07/2008
9	Therapeutics 01/2021 - 07/2009
4	Lymph Node Excision (Lymph Node Dissection) 07/2016 - 09/2011
2	Intravenous Injections 10/2021 - 03/2016
1	Cytoreduction Surgical Procedures 12/2022
1	Treatment Delay 11/2019
1	Castration 11/2019
1	Duration of Therapy 07/2019
1	Radiotherapy 01/2019
1	Injections 02/2013